Blockage of IL-6 and IL-8 in combination with nivolumab is being investigated in phase 1 clinical trials for several carcinomas, including HNSCC for IL-8 (clinical trial identifiers #NCT03400332, #NCT04848116, #NCT03999749). The gene discussed is CXCL8; the disease is carcinoma.